Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $37.9600 (3.41%) ($37.9600 - $38.1400) on Tue. Jul. 20, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.77% (three month average) | RSI | 52 | Latest Price | $37.9600(3.41%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -0.4% a day on average for past five trading days. | Weekly Trend | TGTX declines -2.8% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(68%) ARKG(63%) ARKK(59%) IWO(59%) IBB(58%) | Factors Impacting TGTX price | TGTX will decline at least -1.385% in a week (0% probabilities). VIXM(-46%) VXX(-38%) UUP(-19%) UNG(-4%) TLT(-2%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.385% (StdDev 2.77%) | Hourly BBV | 1.5 () | Intraday Trend | 0% | | | |
|
Resistance Level | $38.45 | 5 Day Moving Average | $37.17(2.13%) | 10 Day Moving Average | $37.98(-0.05%) | 20 Day Moving Average | $38.45(-1.27%) | To recent high | -14.8% | To recent low | 17% | Market Cap | $4.808b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |